latitude supports first-line abiraterone use for metastatic prostate cancer | kim chi
Published 5 years ago • 244 plays • Length 6:39Download video MP4
Download video MP3
Similar videos
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
1:34
dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
-
1:18
results of the latitude trial in high-risk metastatic hormone-naive prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
7:00
comparing the second generation hormone therapies | ask a prostate expert, mark scholz, md
-
1:32:31
unlocking the power of modern therapeutic regimens for prostate cancer
-
3:48
olaparib zytiga for metastatic castrate-resistant prostate cancer | learn about clinical trials
-
1:17
dr. chi discusses the latitude study in metastatic prostate cancer
-
1:10
abiraterone: a new therapy for metastatic prostate cancer | memorial sloan kettering
-
2:12
abiraterone for metastatic, hormone sensitive, prostate cancer
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
1:38
5-year follow up of short-course abiraterone and adt for high-risk prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
5:17
abiraterone alone likely suppresses testosterone sufficiently in mcrpc patients | carsten ohlmann
-
4:18
abiraterone with or without enzalutamide plus adt for non-metastatic prostate cancer
-
0:39
stereotactic body rt in patients with oligometastatic crpc undergoing 1l treatment with abiraterone
-
10:21
profound: olaparib vs enzalutamide or abiraterone for mcrpc with hrr gene alterations
-
4:33
4 most asked questions about abiraterone
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
2:06
dr. chi on androgen deprivation therapy for high-risk metastatic hormone-naive prostate cancer
-
1:08
dr. graff on the use of abiraterone in metastatic prostate cancer